MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Treatments

Home
Treatments

Mitochondrial Dysfunction & ER Stress in MS

MStranslate
April 4, 2017
Research, Treatments
Research Summary: Rab32 connects ER stress to mitochondrial defects in multiple sclerosis Mitochondria are often referred to as the ‘powerhouses’ of the cell, as they are largely responsible for the...
Ocrevus

US FDA Approves Ocrelizumab (Ocrevus)

MStranslate
March 30, 2017
Ocrelizumab, Treatments
Ocrelizumab (Ocrevus) has been granted US FDA approval for the treatment of both replacing-remitting MS (RRMS) and primary progressive MS (PPMS).  Ocrelizumab is a monoclonal antibody that targets and...
apitope

Apitope Announce Positive Peptide Therapy Results

MStranslate
February 28, 2017
Research, Treatments
Imagine you have a dog and a cat and they keep fighting. Solution 1: give one of your pets to someone else. Solution 2: Teach them to get along. Solution 1 describes almost all current MS...
HALT-MS

HALT-MS: Five Year Study Results

MStranslate
February 2, 2017
Research, Stem Cells, Treatments
Research Summary: High dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS The 5 year results of the HALT-MS trial were today published in Neurology.  The HALT-MS clinical trial has...
Alemtuzumab

Case Studies Reveal New Alemtuzumab Side-effects

MStranslate
January 26, 2017
Alemtuzumab, Research, Treatments
Research Summary: Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy A recent report in Lancet Neurology has highlighted two case studies of severe side effects in people with MS receiving...
dimethyl fumarate

Dimethyl Fumarate Linked to Liver Injury

MStranslate
January 17, 2017
Dimethyl fumarate, Research, Treatments
Research Summary: Liver injury associated with dimethyl fumarate in multiple sclerosis patients Last Friday, members of the Office of Surveillance and Epidemiology at the US FDA published a brief report in...
Ocrevus

Ocrelizumab in Primary Progressive MS

MStranslate
January 13, 2017
Ocrelizumab, Research, Treatments
Research Summary: Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis There has been a lot of hype over ocrelizumab as the next ‘wonder drug’ in MS.  This has mostly come from the early...
AHSCT

MS: Many Stories – The AHSCT Experience – Aziz

MStranslate
December 19, 2016
MS: Many Stories, Stem Cells, Treatments
Personal Experiences of Undergoing AHSCT for Multiple Sclerosis Our "MS: Many Stories" series is all about having members of the MStranslate community share insights into different aspects of their journey...
AHSCT

MS: Many Stories – The AHSCT Experience – Mark

MStranslate
December 19, 2016
MS: Many Stories, Stem Cells, Treatments
Personal Experiences of Undergoing AHSCT for Multiple Sclerosis Our "MS: Many Stories" series is all about having members of the MStranslate community share insights into different aspects of their journey...
high-dose biotin

High-dose Biotin Clinical Trial Results

MStranslate
September 13, 2016
Biotin, Clinical Trials, Research, Treatments
1 Comment
Research Summary: MD1003 (high-dose biotin) for the treatment of multiple sclerosis: A randomised, double-blind, placebo-controlled study The background Whilst many treatments are now available for...
  1. 3
  2. 4
  3. 5
  4. 6
  5. 7
  6. 8
  7. 9

Recent Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Jan    

Archives

Categories

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.